Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous No

Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer is a phase 3, randomised interventional study registered as NCT07383116 by Shanghai Huaota Biopharmaceutical Co., Ltd., with a registry enrolment figure of 500 participants, started 2026-01-15 and due to reach its primary completion in 2028-04-10. Interventions recorded: Pemetrexed injection; Carboplatin Injection; Cisplatin injection; HB0025 Injection; Tislelizumab. Conditions listed: Non Squamous Non-small Cell Lung Cancer. Primary outcome: Progression-free survival (PFS). Lung eligibility wording from the registry: "Histologically or cytologically confirmed locally advanced (Stage IIIB/IIIC) or metastatic (Stage IV) non-squamous non-small cell lung cancer (NSCLC) (confirmed per the 9th Edition of the TNM Staging System for Lung Cancer by the Union for International Cancer Control \[UICC\] and the American Joint". Sites: China. No results are recorded here; the registry entry is the source.